RAMPART: quality of life with adjuvant durvalumab in renal cell carcinoma
RCC Content Hub
Sophie Merrick, MBCHB, MRCP, University College London, London, UK, discusses patient-reported quality-of-life outcomes from the RAMPART (NCT03288532) trial of one year of adjuvant durvalumab versus active monitoring in patients with resected intermediate- or high-risk renal cell carcinoma. Durvalumab was associated with small but clinically meaningful early worsening of overall quality of life, role and cognitive function, fatigue, and appetite loss. While overall quality of life and role function recovered over time, cognitive, fatigue, and appetite effects persisted, with later changes in dyspnea and constipation warranting cautious interpretation. This interview took place at the European Society for Medical Oncology (ESMO) 2026 Congress in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.